A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
12/2004
12/09/2004	US20040248865 Synergistic mixture containing antiinflammatory agents; rheumatic disorders
12/09/2004	US20040248863 Combination of a ppar-alpha ligand and glucocorticoid for the treatment or prevention of inflamation
12/09/2004	US20040248844 Method for the treatment or prevention of Flavivirus infections using nucleoside analogues
12/09/2004	US20040248834 Suppressors of cpg oligonucleotides and methods of use
12/09/2004	US20040248833 Therapeutic delivery compositions and methods of use thereof
12/09/2004	US20040248830 Agents that regulate apoptosis
12/09/2004	US20040248829 Gene expression in embryonic pancreas cells, adipocytes; prevent metabolic disorders; antidiabetic agents; obesity; eating disorders; neurodegenerative disorders
12/09/2004	US20040248825 Use of neuraminidase inhibitors to prevent flu associated bacterial infections
12/09/2004	US20040248822 Reducing, controlling weight gain; administering estrogen and, or androgen
12/09/2004	US20040248820 Administering 2-phthalimidoglutaric acid; vision defects; antitumor agents; anticancer agents
12/09/2004	US20040248817 Therapy for cardiovascular disorders; hypotensive agents; congestive heart failure
12/09/2004	US20040248813 Compounds and methods for the modulation of cd154
12/09/2004	US20040248789 peptides/fusion inhibitors;
12/09/2004	US20040248788 preventing or delaying the onset by administration of growth hormone to a mammal predisposed to essential or primary hypertension; such as when subjected to intrauterine undernutrution
12/09/2004	US20040248781 Therapeutic method for reducing angiogenesis
12/09/2004	US20040248769 hydrolytic; inhibits arginyl endopeptidase or serine protease activity; air cleaner; fabric treatment
12/09/2004	US20040248767 Modulating serum amyloid a interaction with tanis and agents useful for same
12/09/2004	US20040248722 Methods for forming hardened tubes and sheets
12/09/2004	US20040248324 Fhm a novel member of the TNF ligand supergene family: materials and methods for interaction modulators
12/09/2004	US20040248252 Nucleotide sequences coding mammalian histamine H4 receptor protein for use in diagnosis, prevention and treatment of asthma, allergy, inflammation, thrombotic, cardiovascular and autoimmune disorders
12/09/2004	US20040248251 Receptors and membrane associated proteins
12/09/2004	US20040248249 Protein for use in treatment, prevention and diagnosis of cell proliferative, autoimmune/inflammatory, cardiovascular, neurological, and developmental disorders
12/09/2004	US20040248243 Lipid metabolizing polypeptide for use in identifying modulators for treatment and prevention of cancer, nervous system, autoimmune/inflammatory, gastrointestinal and cardiovascular disorders
12/09/2004	US20040248233 Using propyl hydroxylase expression system to identify modulators which interfere with or prevent generation of hypoxic states; screening modulator for treatment and prevention of cell proliferative and thrombotic disorder
12/09/2004	US20040248231 Using reduction in beta site amyloid precursor protein cleaving enzyme activity, manifested as decreased beta amyloid peptides production, as diagnostic indicator of enzyme inhibition; for use in treatment of amyloid deposition disorders
12/09/2004	US20040248207 Sodium channel regulators and modulators
12/09/2004	US20040248196 Methods of screening based on the egf receptor crystal structure
12/09/2004	US20040248178 Nucleotide sequences coding neuronal outgrowth and stability protein for use in treating ovarian, renal, neurological, cell proliferative and cardiovascular disorders
12/09/2004	US20040248173 Nucleotide sequences coding cyclic peptide receptor for use in identifying modulators for treatment of pituitary hormone, epinephrine release, gastrointestinal, cardiovascular, electrolyte balance, hypertensive, diabetic and respiratory system disorder
12/09/2004	US20040248124 Nucleic acid encoding polypeptide involved in cellular entrance of the prrs virus
12/09/2004	US20040248078 Contacting osteoblast and osteocyte with either a glucocorticoid alone or in combination with test compound and comparing number of osteoblast and osteocyte undergoing apoptosis, lowered number of apoptotic cells indicates test compound is modulator of glucocorticoid induced osteoporosis
12/09/2004	US20040247713 Topical anti-cancer compositions and methods of use thereof
12/09/2004	US20040247697 Composition with dehydration preventive ingredients
12/09/2004	US20040247696 Administering at least one metal oxide compound having metal cation of first valance state and second metal oxide compound having metal cation of second valance state, other than first, for preventing, treating, or managing foot and mouth disease in an animal
12/09/2004	US20040247686 Pharmaceutical compositions comprising epinastine for the treatment of skin diseases
12/09/2004	US20040247683 Aminoglucosides, such as streptomycin; oral dosage form; tuberculosis
12/09/2004	US20040247674 Drug delivery system
12/09/2004	US20040247650 Zinc, copper, selenium or iron bound to or absorbed into the material matrix; wound healing agents; neovascularization; antiulcer agents; burn treatments before skin transplants; acute infections
12/09/2004	US20040247643 A miniature coated tablet or covered rod implant; smaller size and larger payloads than immediate release tablets; veterinary medicine
12/09/2004	US20040247634 Treatment of parasitic disease
12/09/2004	US20040247633 Novel dermatological composition
12/09/2004	US20040247628 Kit for the preparation of a pharmaceutical composition
12/09/2004	US20040247618 Nutrient absorption enhancing compositions and methods
12/09/2004	US20040247598 In particular of delayed-type hypersensitivity; especially administering an IL-18 binding protein or a derivative, an expression vector or a genetically engineered cell, optionally with an antiinflammatory agent such as a COX-inhibitor.
12/09/2004	US20040247597 Method of treating atherosclerosis and other inflammatory diseases
12/09/2004	US20040247595 Related to the potassium channel subfamily; can be used as models for the development of and aid in the identification of therapeutic proteins that modulate transporter activity
12/09/2004	US20040247564 Treating a tissue disorder involving a loss and/or apoptosis of cells by administering an agent that induces phosphorylation and/or activation of protein kinase B to cause proliferation; particularly administering a human stromal-derived factor-1 and a G-CSF to cause proliferation of cardiomyocytes
12/09/2004	US20040247560 Improved palatability, especially masking the bitter taste of quinolone antibiotics; particle size of less than 50 mu m. delays the formation of a sediment and means that the sediment is very easy to reagitate.
12/09/2004	US20040244713 Method for treating animals or masses of water with compositions comprising quinone compounds
12/09/2004	DE10322497A1 Prophylaxis or therapy of hyperacusis symptoms comprises topical application of local anesthetic, e.g. lidocaine, to skin of outer ear
12/09/2004	DE10321912A1 Preparation of a sun cream for applying to the skin when sunbathing comprises thoroughly mixing panthenol cream and prednisolone ointment to form a uniform mass, mixing in olive oil and pure alcohol and adding fat-soluble perfume
12/09/2004	DE10321905A1 Verwendung von Kombinationen aus Hemmern der reversen Transkriptase und Hemmern der viruscodierten DNA-Polymerase Using combinations of reverse transcriptase inhibitors and inhibitors of the virus-coded DNA polymerase
12/09/2004	DE10312360A1 Active agent combinations of antibiotic and blood thinning agent, useful for combating antibiotic-resistant microorganisms, e.g. in medicinal or disinfectant applications
12/09/2004	CA2527722A1 Biodegradable poly(beta-amino esters) and uses thereof
12/09/2004	CA2527145A1 Use of iron for treating attention deficit hyperactivity disorder in children
12/09/2004	CA2526883A1 A pharmaceutical composition comprising a p2x7-receptor antagonist and a tumour necrosis factor .alpha.
12/09/2004	CA2526566A1 Pharmaceutical combinations of a proton pump inhibitor and a compound which modifies gastrointestinal motility
12/09/2004	CA2525973A1 Combination chemotherapy comprising capecitabine and a liposomal platinum complex
12/09/2004	CA2525952A1 Combination chemotherapy comprising gemcitabine and a liposomal platinum complex
12/09/2004	CA2525908A1 Rock flour, especially dolomite-based medicament, for the treatment of cancer diseases
12/09/2004	CA2525692A1 Cosmetic and/or pharmaceutical compositions comprising dimthylsulphone for the cure and prevention of irritation, inflammation and cutaneous erythema
12/09/2004	CA2524750A1 Composition comprising progesterone-receptor antagonists and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases
12/09/2004	CA2519835A1 Method of treating corneal transplant rejection
12/08/2004	EP1484400A1 Sodium-independent transporter carrying acidic amino acid and its gene
12/08/2004	EP1484332A2 Lipid-based drug delivery system for administration of a drug substance
12/08/2004	EP1484059A2 Antiviral composition comprising phenylacetic acid derivatives
12/08/2004	EP1484058A2 Pharmaceutical composition for inhibiting altering gene expression and for inducing differentiation in non-malignant cells
12/08/2004	EP1483400A1 Use of the axl receptor for diagnosis and treatment of renal disease
12/08/2004	EP1483389A2 Genetic products differentially expressed in tumors and use thereof
12/08/2004	EP1483374A2 Use of l-alpha-lysophosphatidycholine to obtain the differentiation of monocytes in mature dendritric cells in vivo
12/08/2004	EP1483372A2 Functionalization of t cell derived vesicles and use thereof for the preparation of immunogenic pharmaceutical compositions
12/08/2004	EP1483288A2 Hbm variants that modulate bone mass and lipid levels
12/08/2004	EP1483267A2 Microtubule stabilizing compounds
12/08/2004	EP1483251A1 C3-cyano epothilone derivatives
12/08/2004	EP1483232A1 Salts of nateglinide
12/08/2004	EP1483228A1 Nk1 antagonists
12/08/2004	EP1482988A1 METHOD OF RADIO−LABELLING BIOMOLECULES
12/08/2004	EP1482984A2 Surrogate antibodies and methods of preparation and use thereof
12/08/2004	EP1482980A1 Prostaglandin composition for the treatment of erectile dysfunction
12/08/2004	EP1482978A1 Pharmaceutical composition comprising osteoclastogenesis inhibitory factor
12/08/2004	EP1482977A1 Combination therapies for treating methylthioadenosine phosphorylase deficient cells
12/08/2004	EP1482976A1 A preparation and method for weight reduction
12/08/2004	EP1482971A1 Strategy for retroviral immunotherapy
12/08/2004	EP1482970A1 Cancer therapy
12/08/2004	EP1482968A2 Treatment of type i diabetes mellitus using growth hormone antagonist
12/08/2004	EP1482967A1 Pharmaceutical and cosmetic compositions comprising plgf-1
12/08/2004	EP1482962A2 Method of treating trx mediated diseases
12/08/2004	EP1482953A1 Alpha-substituted heteroarylalkyl phosphonate derivattives
12/08/2004	EP1482952A2 Therapeutic and prophylactic treatment of aging and disorders of aging in humans
12/08/2004	EP1482948A1 Continuous sulfatase inhibiting progestogen hormone replacement therapy
12/08/2004	EP1482943A2 Dosing regimen for gemcitabine hcv therapy
12/08/2004	EP1482940A2 Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade
12/08/2004	EP1482938A1 Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist
12/08/2004	EP1482931A2 Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
12/08/2004	EP1482929A1 Use of substituted 3-phenyl-5-alkoxy-1,3,4-oxdiazole-2-one for producing medicaments that inhibit pancreatic lipase
12/08/2004	EP1482924A2 Cathepsin cysteine protease inhibitors
12/08/2004	EP1482922A1 Agents for corneal or intrastromal administration to treat or prevent disorders of the eye
12/08/2004	EP1482921A1 Methods of treating attention deficit/hyperactivity disorder (adhd)
12/08/2004	EP1482916A2 Schwann cell and phosphodiesterase inhibitors based therapy
12/08/2004	EP1482858A2 Methods for aneurysm repair

1 ... 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 ... 1151